Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations

Research output: Contribution to journalArticle

Standard

Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations. / Siwowska, Klaudia; Guzik, Patrycja; Domnanich, Katharina A.; Monné Rodriguez, Josep M.; Bernhardt, Peter; Ponsard, Bernard; Hasler, Roger; Borgna, Francesca; Schibli, Roger; Köster, Ulli; van der Meulen, Nicholas P.; Müller, Cristina.

In: Pharmaceutics, Vol. 11, No. 8, 20.08.2019, p. 1-13.

Research output: Contribution to journalArticle

Harvard

Siwowska, K, Guzik, P, Domnanich, KA, Monné Rodriguez, JM, Bernhardt, P, Ponsard, B, Hasler, R, Borgna, F, Schibli, R, Köster, U, van der Meulen, NP & Müller, C 2019, 'Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations', Pharmaceutics, vol. 11, no. 8, pp. 1-13. https://doi.org/10.3390/pharmaceutics11080424

APA

Siwowska, K., Guzik, P., Domnanich, K. A., Monné Rodriguez, J. M., Bernhardt, P., Ponsard, B., ... Müller, C. (2019). Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations. Pharmaceutics, 11(8), 1-13. https://doi.org/10.3390/pharmaceutics11080424

Vancouver

Siwowska K, Guzik P, Domnanich KA, Monné Rodriguez JM, Bernhardt P, Ponsard B et al. Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations. Pharmaceutics. 2019 Aug 20;11(8):1-13. https://doi.org/10.3390/pharmaceutics11080424

Author

Siwowska, Klaudia ; Guzik, Patrycja ; Domnanich, Katharina A. ; Monné Rodriguez, Josep M. ; Bernhardt, Peter ; Ponsard, Bernard ; Hasler, Roger ; Borgna, Francesca ; Schibli, Roger ; Köster, Ulli ; van der Meulen, Nicholas P. ; Müller, Cristina. / Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations. In: Pharmaceutics. 2019 ; Vol. 11, No. 8. pp. 1-13.

Bibtex - Download

@article{e55bc2bed84f4fe69b32f4698617cab3,
title = "Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations",
abstract = "Targeted radionuclide therapy with 177Lu- and 90Y-labeled radioconjugates is a clinicallyestablished treatment modality for metastasized cancer. 47Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy 蚠-particles. In this study, 47Sc was investigated, in combination with a DOTA-folate conjugate, and compared to the therapeutic properties of 177Lu-folate and 90Y-folate, respectively. In vitro, 47Sc-folate demonstrated effective reduction of folate receptor-positive ovarian tumor cell viability similar to 177Lu-folate, but 90Y-folate was more potent at equal activities due to the higher energy of emitted 蚠-particles. Comparable tumor growth inhibition was observed in mice that obtained the same estimated absorbed tumor dose (~21 Gy) when treated with 47Sc-folate (12.5MBq), 177Lu-folate (10MBq), and 90Y-folate (5MBq), respectively. The treatment resulted in increased median survival of 39, 43, and 41 days, respectively, as compared to 26 days in untreated controls. There were no statistically significant differences among the therapeutic effects observed in treated groups. Histological assessment revealed no severe side effects two weeks after application of the radiofolates, even at double the activity used for therapy. Based on the decay properties and our results, 47Sc is likely to be comparable to 177Lu when employed for targeted radionuclide therapy. It may, therefore, have potential for clinical translation and be of particular interest in tandem with 44Sc or 43Sc as a diagnostic match, enabling the realization of radiotheragnostics in future.",
keywords = "Radionucliede therapy, SPECT, folate receptor, DOTA-folate, IGROV-1 tumor xenografts, preclinical therapy, 177-Lu, 47-Sc, 90Y",
author = "Klaudia Siwowska and Patrycja Guzik and Domnanich, {Katharina A.} and {Monn{\'e} Rodriguez}, {Josep M.} and Peter Bernhardt and Bernard Ponsard and Roger Hasler and Francesca Borgna and Roger Schibli and Ulli K{\"o}ster and {van der Meulen}, {Nicholas P.} and Cristina M{\"u}ller",
note = "Score=10",
year = "2019",
month = "8",
day = "20",
doi = "10.3390/pharmaceutics11080424",
language = "English",
volume = "11",
pages = "1--13",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "MDPI",
number = "8",

}

RIS - Download

TY - JOUR

T1 - Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations

AU - Siwowska, Klaudia

AU - Guzik, Patrycja

AU - Domnanich, Katharina A.

AU - Monné Rodriguez, Josep M.

AU - Bernhardt, Peter

AU - Ponsard, Bernard

AU - Hasler, Roger

AU - Borgna, Francesca

AU - Schibli, Roger

AU - Köster, Ulli

AU - van der Meulen, Nicholas P.

AU - Müller, Cristina

N1 - Score=10

PY - 2019/8/20

Y1 - 2019/8/20

N2 - Targeted radionuclide therapy with 177Lu- and 90Y-labeled radioconjugates is a clinicallyestablished treatment modality for metastasized cancer. 47Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy 蚠-particles. In this study, 47Sc was investigated, in combination with a DOTA-folate conjugate, and compared to the therapeutic properties of 177Lu-folate and 90Y-folate, respectively. In vitro, 47Sc-folate demonstrated effective reduction of folate receptor-positive ovarian tumor cell viability similar to 177Lu-folate, but 90Y-folate was more potent at equal activities due to the higher energy of emitted 蚠-particles. Comparable tumor growth inhibition was observed in mice that obtained the same estimated absorbed tumor dose (~21 Gy) when treated with 47Sc-folate (12.5MBq), 177Lu-folate (10MBq), and 90Y-folate (5MBq), respectively. The treatment resulted in increased median survival of 39, 43, and 41 days, respectively, as compared to 26 days in untreated controls. There were no statistically significant differences among the therapeutic effects observed in treated groups. Histological assessment revealed no severe side effects two weeks after application of the radiofolates, even at double the activity used for therapy. Based on the decay properties and our results, 47Sc is likely to be comparable to 177Lu when employed for targeted radionuclide therapy. It may, therefore, have potential for clinical translation and be of particular interest in tandem with 44Sc or 43Sc as a diagnostic match, enabling the realization of radiotheragnostics in future.

AB - Targeted radionuclide therapy with 177Lu- and 90Y-labeled radioconjugates is a clinicallyestablished treatment modality for metastasized cancer. 47Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy 蚠-particles. In this study, 47Sc was investigated, in combination with a DOTA-folate conjugate, and compared to the therapeutic properties of 177Lu-folate and 90Y-folate, respectively. In vitro, 47Sc-folate demonstrated effective reduction of folate receptor-positive ovarian tumor cell viability similar to 177Lu-folate, but 90Y-folate was more potent at equal activities due to the higher energy of emitted 蚠-particles. Comparable tumor growth inhibition was observed in mice that obtained the same estimated absorbed tumor dose (~21 Gy) when treated with 47Sc-folate (12.5MBq), 177Lu-folate (10MBq), and 90Y-folate (5MBq), respectively. The treatment resulted in increased median survival of 39, 43, and 41 days, respectively, as compared to 26 days in untreated controls. There were no statistically significant differences among the therapeutic effects observed in treated groups. Histological assessment revealed no severe side effects two weeks after application of the radiofolates, even at double the activity used for therapy. Based on the decay properties and our results, 47Sc is likely to be comparable to 177Lu when employed for targeted radionuclide therapy. It may, therefore, have potential for clinical translation and be of particular interest in tandem with 44Sc or 43Sc as a diagnostic match, enabling the realization of radiotheragnostics in future.

KW - Radionucliede therapy

KW - SPECT

KW - folate receptor

KW - DOTA-folate

KW - IGROV-1 tumor xenografts

KW - preclinical therapy

KW - 177-Lu

KW - 47-Sc

KW - 90Y

UR - http://ecm.sckcen.be/OTCS/llisapi.dll/open/35144998

U2 - 10.3390/pharmaceutics11080424

DO - 10.3390/pharmaceutics11080424

M3 - Article

VL - 11

SP - 1

EP - 13

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 8

ER -

ID: 5550788